Table 2.
HLA, APM and β2m expression in RST and HNPCC colon cancer
| HLA† | APM loss ‡ | β2m loss ‡ | |||
| RST N = 81 |
MSS | + | 40 | 0 | 0 |
| N = 48 (59,3%) |
- | 8 (16,7%) | 3 (37,5%)* | 0 | |
| MSI-H | + | 13 | 0 | 0 | |
| N = 33 (41,7%) |
- | 20 (60,6%) | 7 (35,0%)* | 1 (5,0%)* | |
| HNPCC N = 75 |
MSI-H | + | 43 | 0 | 0 |
| - | 32 (42,7%) | 2 (6,3%)* | 15 (46,9%)* | ||
* – The percentage of cases that lost APM or β2m expression is relative to the number of HLA negative cases of each subset
† – HLA expression differs significantly between sporadic MSI-H and MSS tumors (p < 0.0001) and between HNPCC and sporadic MSS tumors (p < 0.005)
‡ – The association of HLA class I loss with that of β2m and of APM components differs significantly (p < 0.0001) between sporadic RST and HNPCC tumors.